Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||acute myeloid leukemia||not applicable||Galinpepimut-S||Phase II||Actionable||In a Phase II trial, Galinpepimut-S treatment in adults with acute myeloid leukemia in their first complete remission (CR1) was well tolerated and resulted in a median disease free survival of 16.9 months from CR1, 47% (9/19) survival beyond 3 years in evaluable patients, and immunologic responses in 64% (9/14) of patients tested (PMID: 29386195; NCT01266083).||29386195|